Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Int Soc Sports Nutr ; 18(1): 9, 2021 Jan 13.
Artículo en Inglés | MEDLINE | ID: mdl-33441158

RESUMEN

BACKGROUND: Exercise-induced muscle damage (EIMD) results in transient muscle inflammation, strength loss, muscle soreness and may cause subsequent exercise avoidance. Omega-3 (n-3) supplementation may minimise EIMD via its anti-inflammatory properties, however, its efficacy remains unclear. METHODS: Healthy males (n = 14, 25.07 ± 4.05 years) were randomised to 3 g/day n-3 supplementation (N-3, n = 7) or placebo (PLA, n = 7). Following 4 weeks supplementation, a downhill running protocol (60 min, 65% V̇O2max, - 10% gradient) was performed. Creatine kinase (CK), interleukin (IL)-6 and tumour necrosis factor (TNF)-α, perceived muscle soreness, maximal voluntary isometric contraction (MVIC) and peak power were quantified pre, post, and 24, 48 and 72 h post-EIMD. RESULTS: Muscle soreness was significantly lower in N-3 vs PLA group at 24 h post-EIMD (p = 0.034). IL-6 was increased in PLA (p = 0.009) but not in N-3 (p = 0.434) following EIMD, however, no significant differences were noted between groups. Peak power was significantly suppressed in PLA relative to pre-EIMD but not in N-3 group at 24 h post-EIMD. However, no significant difference in peak power output was observed between groups. MVIC, CK and TNF-α were altered by EIMD but did not differ between groups. CONCLUSION: N-3 supplementation for 4 weeks may successfully attenuate minor aspects of EIMD. Whilst not improving performance, these findings may have relevance to soreness-associated exercise avoidance.


Asunto(s)
Ejercicio Físico , Ácidos Grasos Omega-3/farmacología , Enfermedades Musculares/terapia , Miositis/terapia , Adulto , Análisis de Varianza , Biomarcadores/sangre , Creatina Quinasa/sangre , Ácidos Grasos Omega-3/administración & dosificación , Humanos , Interleucina-6/sangre , Contracción Isométrica , Masculino , Fuerza Muscular , Debilidad Muscular/etiología , Debilidad Muscular/terapia , Músculo Esquelético/lesiones , Enfermedades Musculares/sangre , Enfermedades Musculares/etiología , Mialgia/terapia , Miositis/etiología , Carrera , Factores de Tiempo , Factor de Necrosis Tumoral alfa/sangre
2.
Open Heart ; 7(2)2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32938758

RESUMEN

Risk factors for COVID-19 patients with poorer outcomes include pre-existing conditions: obesity, type 2 diabetes mellitus, cardiovascular disease (CVD), heart failure, hypertension, low oxygen saturation capacity, cancer, elevated: ferritin, C reactive protein (CRP) and D-dimer. A common denominator, hyperinsulinaemia, provides a plausible mechanism of action, underlying CVD, hypertension and strokes, all conditions typified with thrombi. The underlying science provides a theoretical management algorithm for the frontline practitioners.Vitamin D activation requires magnesium. Hyperinsulinaemia promotes: magnesium depletion via increased renal excretion, reduced intracellular levels, lowers vitamin D status via sequestration into adipocytes and hydroxylation activation inhibition. Hyperinsulinaemia mediates thrombi development via: fibrinolysis inhibition, anticoagulation production dysregulation, increasing reactive oxygen species, decreased antioxidant capacity via nicotinamide adenine dinucleotide depletion, haem oxidation and catabolism, producing carbon monoxide, increasing deep vein thrombosis risk and pulmonary emboli. Increased haem-synthesis demand upregulates carbon dioxide production, decreasing oxygen saturation capacity. Hyperinsulinaemia decreases cholesterol sulfurylation to cholesterol sulfate, as low vitamin D regulation due to magnesium depletion and/or vitamin D sequestration and/or diminished activation capacity decreases sulfotransferase enzyme SULT2B1b activity, consequently decreasing plasma membrane negative charge between red blood cells, platelets and endothelial cells, thus increasing agglutination and thrombosis.Patients with COVID-19 admitted with hyperglycaemia and/or hyperinsulinaemia should be placed on a restricted refined carbohydrate diet, with limited use of intravenous dextrose solutions. Degree/level of restriction is determined by serial testing of blood glucose, insulin and ketones. Supplemental magnesium, vitamin D and zinc should be administered. By implementing refined carbohydrate restriction, three primary risk factors, hyperinsulinaemia, hyperglycaemia and hypertension, that increase inflammation, coagulation and thrombosis risk are rapidly managed.


Asunto(s)
Infecciones por Coronavirus/terapia , Dieta Baja en Carbohidratos , Suplementos Dietéticos , Hiperinsulinismo/terapia , Insulina/sangre , Magnesio/uso terapéutico , Neumonía Viral/terapia , Trombosis/terapia , Vitamina D/uso terapéutico , Betacoronavirus/patogenicidad , Biomarcadores/sangre , Glucemia/metabolismo , COVID-19 , Infecciones por Coronavirus/sangre , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/virología , Suplementos Dietéticos/efectos adversos , Interacciones Huésped-Patógeno , Humanos , Hiperinsulinismo/sangre , Hiperinsulinismo/epidemiología , Cetonas/sangre , Magnesio/sangre , Pandemias , Neumonía Viral/sangre , Neumonía Viral/epidemiología , Neumonía Viral/virología , Pronóstico , Factores de Riesgo , SARS-CoV-2 , Trombosis/sangre , Trombosis/epidemiología , Trombosis/virología , Vitamina D/sangre , Zinc/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA